Expert Illustrations & Commentaries™: Roles and Rationales for BCMA-Directed Therapies in Multiple Myeloma

CME: 1.0

Target Audience

This educational program is directed toward medical oncologists/hematologists, and other oncology HCPs involved in the treatment of multiple myeloma. Advanced practitioners, nurses, pharmacists, and other healthcare professionals interested in multiple myeloma will be invited to participate.

Program Overview

This Expert Illustrations and CommentariesTM online activity is a video-based program in which 2 experts discuss emerging treatments in multiple myeloma (MM), namely B-cell directed maturation antigen (BCMA) therapy. In this activity, the faculty focus on treatments for both newly diagnosed (ND) and relapsed/refractory (RR) multiple myeloma. Their discussion is enriched with the addition of video animations to illustrate the mechanism of action of various BCMA therapies, including antibody-drug conjugates (ADC), bispecific T-cell engagers (BiTE), and chimeric antigen receptor (CAR) T-cell agents. This unique format is designed to help clinicians understand the mechanism of emerging agents to identify best practices in the treatment of MM and to improve outcomes for their patients with this disease.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the rationale for targeting BCMA in R/R MM and the mechanisms of action for therapeutic agents acting through BCMA
  • Assess pivotal trials’ results from studies that evaluated current and emerging BCMA-targeted agents evaluated for the treatment of patients with R/R MM
  • Implement strategies to promptly identify and mitigate toxicities associated with agents targeting BCMA in R/R MM

Post a comment to this article